Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02330029
Other study ID # D00320141210
Secondary ID
Status Active, not recruiting
Phase N/A
First received December 29, 2014
Last updated November 18, 2016
Start date August 2012
Est. completion date May 2017

Study information

Verified date November 2016
Source Macrohard Institute of Health
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardChina: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the onset of action, offset of action, efficacy, and safety of pinaverium and an herbal medication for irritable bowel syndrome (IBS) for a long term (over one year). Pinaverium has been in many countries, but there is no randomized, double-blind, large sample size, and placebo-controlled study on this medication yet. Tong Xie Yao Fang (Formula for pain and diarrhea) is a historically and contemporarily used traditional Chinese medicine that can be used for IBS. The hypothesis is that the two remedies are effective and safe for IBS treatment with no significant different onset and offset of actions when tested by modern clinical standards and criteria.


Description:

Pinaverium bromide (pinaverium), an antispasmodics, is one of the most commonly used IBS medication worldwide. However, original clinical studies on pinaverium are scarce. Only five original clinical studies from Europe, one from Latin America, and one from Asian were found. These studies were single-centered and small sample sized (19 - 53 IBS patients) studies.

Tong Xie Yao Fang has long been used in China. Its efficacy and safety has not been evaluated by modern scientific method.

Effectiveness, onset and offset of actions are the most considered factors when physicians choose medications for IBS. Yet, to our knowledge, there are no clinical studies studied the onset and offset of actions of pinaverium, which remains one of the most transcribed IBS medications, and herbs, which are becoming more popular for treating IBS.

This study is designed to evaluate onset and offset of actions, efficacy, and safety over a long term (>1 year) of pinaverium and Tong Xie Yao Fang for IBS treatment in a double-blind, randomized, and large sample size clinical trial using placebo as a control.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 800
Est. completion date May 2017
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- 18 to 70 years old age group, male and female

- In accordance with the above Western medicine Rome III standards.

- In accordance with the above description of Deficient Spleen Qi and Liver Qi Stagnation

- Informed consent for treatment

- No change in appetite during treatments periods

Exclusion Criteria:

- Pregnant or lactation female patients, and Fertility male patients

- Present digestive system disease within current three months

- Take IBS medicines within ten days prior to treatment or during treatment

- Take depression medicine within ten days prior to treatment or during treatment

- Take pain reliever medicine within ten days prior to treatment or during treatment

- Have serious primary heart, liver, kidney, lung and blood system diseases, asthma, and Lung and liver dysfunction patients

- If an emergency occurs; a physician terminates the treatment

- Cannot comply with the rules and cannot cooperate

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Pinaverium
To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Device:
Atractylodes
Atractylodes (~10-15g)
Paeonia Lactiflora
Paeonia Lactiflora (~15-30g)
Tangerine Peel
Tangerine Peel (~10g)
Drug:
Ledebouriella Root
Ledebouriella Root (~10g)
Radix codonopsitis
Radix codonopsitis (~10-15g)
Radix curcumae
Radix curcumae (~10g)
Fingered citron
Fingered citron (~10g)
Tuckahoe
Tuckahoe (15g)
Placebo
Placebo is blindly given to patients.

Locations

Country Name City State
China Beijing Xuanwu Hospital of Traditional Chinese Medicine affiliated to Capital Medical University. Beijing
China Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine Nanjing Jiangsu
China Second Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine Nanjing Jiangsu
China Shanghai First People's Hospital affiliated to Shanghai Tiao Tong University Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Macrohard Institute of Health

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other IBS global symptom relief IBS global symptom relief was evaluated by each patient at the end of the therapy as "improved", "stayed the same", or "worsened" 2 years No
Other Treatment-emergent adverse effect (TEAE) profiles. 2 years No
Primary Abdominal pain 0 = no pain, 10 worst pain 2 years No
Primary Primary endpoint --- vi) Form (appearance) of stool Use Bristol stool scale. 2 years No
Secondary Frequency of the pain 0 = no pain; 1 = 1 pain/day; 2 = 2 pains/day; 3 = 3 pains/day; ................... 9 = 9 pains/day; 10 = = 10 pains/day. 2 year No
Secondary # of stools per day 0 = no stool; 1 = 1 stool/day; 2 = 2 stools/day; 3 = 3 stools/day; ............... 9 = 9 stools/day; 10 = = 10 stools/day. 2 years No
Secondary Abdominal discomfort 0 = no discomfort...... 10 = Worst possible, unbearable unbearable discomfort 2 years No
Secondary Frequency of discomfort 0 = no discomfort; 1 = 1 discomfort/day; 2 = 2 discomforts/day; 3 = 3 discomforts /day; ................... 9 = 9 discomforts/day; 10 = = 10 discomforts/day. 2 years No
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A